glp-1 gip medications muscle loss comparison Does GLP-1/GIP Therapy Cause Loss? | What the Science Shows From Fat Burn to Muscle

In the Phase 2 trial published in the New England Journal of Medicine, researchers documented cutaneous hyperesthesia in approximately 7% of retatrutide participants compared to just 1% in the placebo group

The use of dopamine in the treatment of cardiogenic shock (e.g

Monitoring & adjustment : Periodic labs (micronutrients, metabolic markers, lean mass, bone density if relevant), and adjust supplements as needed under provider supervision

Clinician and patient barriers to the recognition of insomnia in family practice: a narrative summary of reported literature analysed using the theoretical domains framework